Search the GHTC website

Global health R&D delivers for Georgia

US government investment in global health R&D has delivered

Amount
$349.1 million
to Georgia research institutions
Jobs
5,800+ new jobs
for Georgia
Georgia's top USG-funded global health R&D institutions

Georgia's top USG-funded global health R&D institutions

Centers for Disease Control and Prevention (self-funding & other agency transfers)
$129.8 million
Emory University
$147.8 million
University of Georgia
$61 million
Morehouse School of Medicine
$4.7 million
Georgia State University
$4.1 million
Augusta University College of Education (formally Georgia Regents University)
$745 thousand
Mercer University
$252 thousand
Medical College of Georgia
$204 thousand
Atlanta Research and Education Foundation
$55 thousand
Georgia industry in global health R&D

Georgia industry in global health R&D

Arthify
Location(s): Duluth
Geovax
Location(s): Atlanta
Novartis
Location(s): Duluth
Pathens
Location(s): Athens
Sanofi
Location(s): Forest Park
Westat
Location(s): Atlanta

Georgia's top areas of global health R&D by USG funding

29.9%
HIV/AIDS
13.9%
Malaria
25.3%
Tuberculosis
4.2%
Ebola/viral hemorrhagic fevers
3.2%
Bacterial pneumonia & meningitis
16.2%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminths
Kinetoplastids
Trachoma
7.3%
Other
Diarrheal diseases
Salmonella infections
Global health R&D at work in Georgia

Emory University School of Medicine is supporting early stage clinical trials of a vaccine to prevent infection with chikungunya virus. Chikungunya is transmitted by mosquitoes and can cause persistent, debilitating joint pain. The virus, originating in Africa, arrived in the Caribbean several years ago and has since infected more than 2 million people in the Americas, including in the Florida Keys. If approved, the vaccine could be a powerful tool for protection.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: Pan American Health Organization